VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | Lentivirally and alpharetrovirally engineered CD19 NK CAR-cells in ALL

Tobias Bexte, cand.med., University Hospital Frankfurt, Goethe University, Frankfurt, Germany, discusses his abstract on lentivirally and alpharetrovirally engineered CD19 specific chimeric antigen receptor (CAR) natural killer (NK) cells and their use in acute lymphoblastic leukemia (ALL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter